13. 多発性硬化症／視神経脊髄炎 Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details
臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00360906 (ClinicalTrials.gov) | December 2004 | 4/8/2006 | Omega-3 Fatty Acid Treatment in Multiple Sclerosis | Omega-3 Fatty Acid Treatment in Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Drug: Triomar™ (omega-3 fatty acids) | Haukeland University Hospital | The Multiple Sclerosis National Competence Centre;The Norwegian Multiple sclerosis Society;Pronova BioPharma;Serono Nordic;Amersham Health | Completed | 18 Years | 55 Years | Both | 100 | Phase 2/Phase 3 | Norway |